Sound Stimulation Aids Saccular Dysfunction With Meniere Disease
By Lori Solomon and Marianne Madeiros HealthDay Reporters
MONDAY, July 1, 2024 -- Sound stimulation of 75 dB at a frequency of 100 Hz leads to improvement in cervical vestibular-evoked myogenic potential (cVEMP) amplitude in patients with definitive Meniere disease, according to a study published online June 24 in Acta Oto-Laryngologica.
Michihiko Sone, M.D., Ph.D., from the Nagoya University Graduate School of Medicine in Japan, and colleagues investigated the efficacy of sound stimulation of 100 Hz for treating vestibular dysfunction in patients with Meniere disease. Analysis included patients with definitive Meniere disease with intractable vestibular symptoms and endolymphatic hydrops in the inner ear who received either sound stimulation of 75 dB at a frequency of 100 Hz for five minutes or sound stimulation of 75 dB at a frequency of 250 Hz for five minutes (control).
The researchers observed significant increases in cVEMP amplitudes after sound stimulation of 100 Hz in ears with vestibular endolymphatic hydrops. No such improvement was seen in the control group.
"Sound stimulation of 75 dB at a frequency of 100 Hz leads to improvement in cVEMP amplitude in patients with definitive Meniere disease," the authors write. "Adequate sound stimulation might be a new method for treating the vestibular dysfunction associated with Meniere disease."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-02 07:15
Read more
- High Rates of Hep C Seen for Patients Presenting to ED With Opioid Overdose
- E. Coli Outbreak Linked to McDonald's Quarter Pounders Widens to 75 Cases in 13 States; 22 Hospitalized
- Complications From Prostate Cancer Therapy Can Be Serious and Long-Term
- FDA Approves Hympavzi for Hemophilia
- Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
- FDA Approves Vyalev for Advanced Parkinson Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions